Radboudumc is the first hospital in the world to use a new genetic test on a large scale in clinical practice. This test provides more people with a diagnosis for rare conditions and is faster and ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Genetic differences in early- and late-onset depression highlight distinct risk profiles, informing targeted strategies for ...

Radboudumc and Maastricht UMC+ are the first hospitals in the world to use a new genetic test to diagnose rare diseases on a ...

Preterm babies face greater health risks from the moment they are born. Their organs, immune systems, and metabolic pathways are not fully developed, making them more vulnerable to complications.

Baylor College of Medicine’s Center for Precision Medicine Models has received a five-year, $10 million grant from the ...

Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for ...

The Ontario Hereditary Cancer Research Network's (OHCRN) participant portal is now open and Ontarians at risk of hereditary cancers are invited to register.

Radboud University teaching hospital has become what it says is the first in the world to use a new genetic test on a large ...

At Mayo Clinic, cardiologists Peter Noseworthy, M.D., and John Giudicessi, M.D., Ph.D., are uncovering the earliest signs of ...